Measles, Mumps, Rubella Vaccine Market Size, Share & Trends Analysis Report By Type (Monovalent, Trivalent), By Target Population (Infants & Children, Adults), By Distribution Channel (Hospitals & Healthcare Institutions), By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global measles, mumps, rubella vaccine market size was estimated at USD 1.82 billion in 2024 and is expected to grow at a CAGR of 8.47% from 2025 to 2030. Measles, mumps, and rubella are viral infections that pose significant risks, particularly to non-immune pregnant women and their unborn children or newborns. The rising prevalence of these diseases and frequent outbreaks are key factors fueling market growth. According to the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC), measles claimed an estimated 107,500 lives globally in 2023, with the majority of victims being children under five. The WHO also reported a 20% increase in global measles cases from 2022 to 2023, totaling approximately 10.3 million infections. As per CDC data from April 2025, seven measles outbreaks-defined as three or more linked cases-were reported, with 93% (660 out of 712) of confirmed cases associated with these outbreaks. In contrast, 2024 saw 16 outbreaks, accounting for 69% (198 out of 285) of total cases.

Outbreaks are largely driven by under-vaccination caused by misinformation, vaccine hesitancy, and under-resourced healthcare systems. In response, governments and public health agencies have launched extensive immunization initiatives aimed at curbing the spread of these diseases. National programs, such as the Expanded Programme on Immunization (EPI), incorporate MMR into standard childhood vaccination schedules. Routine measles immunization, supplemented by mass vaccination campaigns in regions with low coverage, remains a crucial strategy in reducing global measles-related mortality, especially in low-income countries, where about 95% of these deaths occur.

The WHO advocates for two doses of measles vaccine for every child, administered either alone or as part of combination vaccines like MR (measles-rubella), MMR (measles-mumps-rubella), or MMRV (measles-mumps-rubella-varicella). In April 2024, the Iraqi Ministry of Health, with support from UNICEF and WHO, launched a nationwide vaccination campaign targeting over 7.5 million children aged 6 to 12 years to protect against measles, mumps, and rubella.

Public funding and free vaccine distribution are critical for ensuring equitable access, particularly in underserved populations. International organizations such as WHO, UNICEF, Gavi-the Vaccine Alliance-and the Pan American Health Organization (PAHO) play vital roles in supporting global immunization efforts, especially in low- and middle-income countries. Their collaborative initiatives significantly improve vaccine accessibility, equity, and coverage.

Increased public awareness of vaccine-preventable diseases has further contributed to market growth. Awareness efforts, such as WHO's World Immunization Week held during the first week of April 2025, emphasize the importance of vaccines across all age groups. Public health campaigns have been instrumental in improving immunization rates and promoting community-wide protection.

Gavi, the Vaccine Alliance-a global health partnership-has been central to advancing vaccine access in low-income countries. Through innovative financing mechanisms like the International Finance Facility for Immunization (IFFIm), Gavi secures long-term funding to issue bonds, accelerating vaccine procurement and distribution. This model has proven effective in addressing global health emergencies and enhancing access to life-saving immunizations.

Notably, the UK hosted the Global Vaccine Summit in June 2020, aiming to raise USD 7.4 billion to vaccinate 300 million children across 50 countries between 2021 and 2025. These collective efforts have made considerable progress in boosting MMR vaccination rates, yet continued investment and advocacy are essential to ensure comprehensive protection against these preventable diseases for all children worldwide.

Market Concentration & Characteristics

The industry is marked by a significant degree of innovation by enhancing diagnostic accuracy, enabling personalized treatments, and improving patient outcomes, according to the clinical trial conducted in May 2024, in Gambia that assessed the efficacy and safety of a microneedle patch delivering the measles and rubella vaccine. The results demonstrated comparable immune responses between the two methods for all age groups. This trial marks a significant advancement in vaccine delivery technology, offering a promising alternative to traditional injection methods.

The measles, mumps, rubella vaccine sector has experienced notable mergers and acquisitions (M&A) activity, reflecting the strategic importance of vaccines in the global healthcare market. In 2021, Sanofi acquired Translate Bio for USD 3.2 billion, gaining access to mRNA vaccine technology, which has potential applications in developing next-generation vaccines, including those for MMR. Sanofi has actively pursued acquisitions to bolster its vaccine portfolio.

Regulations play a crucial role in shaping the industry, affecting product approvals, market adoption, and innovation. WHO Technical Report Series No. 840 outlines requirements for each component of the vaccine-measles, mumps, and rubella-to ensure they meet international safety and efficacy standards. Additionally, the WHO's Strategic Advisory Group of Experts (SAGE) on Immunization offers recommendations on vaccine introduction and coverage targets. For instance, in September 2024, SAGE recommended lifting the requirement for countries to achieve 80% measles-containing vaccine coverage before introducing rubella-containing vaccines, aiming to accelerate rubella control efforts. Regulatory bodies like the FDA (U.S.), CE Mark (Europe), and CFDA (China) enforce strict guidelines to ensure diagnostic accuracy, patient safety, and data security.

The level of product substitutes for measles, mumps, and rubella (MMR) vaccines is low. There are no effective alternatives to vaccination for preventing these viral diseases. While supportive treatments exist for managing symptoms, they do not offer immunity. Hence, MMR vaccines remain the most reliable and widely endorsed preventive solution, with limited risk of substitution in the market.

The industry exhibits a high level of end-user concentration, primarily driven by demand from hospitals and reference labs, pharma and biotech companies, academic and research institutions and contract research organizations. Large healthcare networks and academic medical centers account for a significant portion of adoption, as they require high-throughput scanning and AI-powered diagnostics. Reference laboratories and contract research organizations (CROs) also contribute to market growth by utilizing digital pathology for clinical trials. While adoption is growing in smaller pathology labs, the market remains concentrated among large-scale institutions with higher diagnostic volumes and technology budgets.

Type Insights

The tetravalent segment accounted for the largest revenue share of 57.37% in 2024 and is anticipated to witness a significant CAGR from 2025 to 2030. This surge is primarily fueled by the growing demand for comprehensive immunization solutions that provide protection against multiple diseases in a single dose. The ability to administer one combined vaccine, rather than multiple separate injections, greatly improves patient compliance and simplifies vaccination schedules, particularly in children, where ease and efficiency are crucial. In addition, advancements in vaccine formulation and technology have led to the development of more stable and effective MMRV vaccines. These innovations make the vaccines better suited for distribution in areas with limited cold-chain infrastructure, expanding access in low-resource settings. Further driving the segment’s growth is the increased investment in production capacity. In March 2025, Merck announced the opening of a new USD 1 billion, 225,000-square-foot vaccine manufacturing facility in Durham, North Carolina. This development is part of Merck's larger commitment to U.S. healthcare infrastructure, representing a portion of the more than USD 12 billion the company has invested in domestic manufacturing and R&D since 2018. Merck also anticipates an additional 8 billion in U.S. capital investment by 2028, underscoring its focus on expanding production capabilities and supporting job creation across the country.

The trivalent vaccine segment is experiencing significant growth within the global industry. This expansion is driven by the vaccine's efficiency in delivering protection against three viral diseases through a single administration, thereby simplifying immunization schedules and improving compliance, especially among pediatric populations. Multivalent vaccines, including the trivalent MMR, have gained prominence due to their ability to reduce the number of injections required, leading to increased vaccination coverage and cost-effectiveness for healthcare systems. Leading pharmaceutical companies, such as Merck & Co., GlaxoSmithKline, and Sanofi Pasteur, are actively involved in the production and distribution of MMR vaccines. Merck's M-M-R II and GSK's Priorix are widely used globally, supported by robust distribution networks and strategic partnerships with governments and health organizations. These collaborations are crucial in reaching underserved populations and expanding immunization coverage.

Target Population Insights

The infants and children (9 months to 12) segment dominated the market with the largest share of 67.96% in 2024 is anticipated to witness a significant CAGR from 2025 to 2030, driven by increasing global immunization efforts and heightened awareness of vaccine-preventable diseases. This demographic is particularly vulnerable to measles, mumps, and rubella, making early vaccination crucial for disease prevention and public health. In regions like Asia-Pacific, countries such as India and China are investing heavily in public health programs to eliminate measles and rubella, contributing to the market's growth. The expansion of healthcare infrastructure and rising awareness about the importance of vaccination further support the positive outlook for the MMR vaccine market among infants and children.

The adult segment is experiencing notable growth, driven by increasing awareness of adult immunization, the resurgence of measles outbreaks, and evolving public health policies. Although traditionally focused on pediatric populations, MMR vaccination is now being emphasized for adults, particularly those who missed childhood immunizations, healthcare workers, international travelers, and individuals in outbreak-prone regions. Despite these advancements, challenges like vaccine hesitancy, lack of awareness, and limited access in certain regions persist. Addressing these barriers through targeted education campaigns, policy support, and infrastructure development is essential to sustain and accelerate the growth of the adult MMR vaccine market.

Distribution Channel Insights

The vaccine centers and public health clinics segment dominated the industry with the largest share of 41.65% in 2024. Public health facilities, including community health centers and public vaccination clinics, are the largest end-users of the MMR vaccine. These facilities are crucial in providing immunization services to the population, especially in regions where the majority relies on public healthcare. Government-funded immunization programs, such as India's Universal Immunization Programme (UIP), have significantly expanded vaccine access. India's UIP targets 30 million pregnant women and 27 million newborns annually, contributing to a substantial reduction in vaccine-preventable mortality rates among children under five. Between 2017 and March 2023, India vaccinated over 348 million children through nationwide measles-rubella campaigns, demonstrating the effectiveness of public health initiatives in increasing vaccine coverage.

Pediatric and private healthcare clinics are projected to grow at a CAGR of 9.12% during the forecast period, driven by increasing demand for personalized healthcare services and enhanced accessibility to immunization. In developed regions, private clinics are integral to national immunization programs, offering flexibility and convenience that appeal to parents seeking timely vaccinations for their children.Economic incentives, such as vaccine bundling agreements, have further propelled this segment's growth. These agreements allow pediatricians to purchase vaccines at discounted rates when committing to buy the majority of their vaccines from a single manufacturer, thereby reducing operational costs and encouraging higher vaccine uptake. However, such practices have raised concerns regarding competition and physician choice.

Regional Insights

North America measles, mumps, and rubella vaccine market is experiencing significant growth, driven by heightened public health initiatives and government interventions. In March 2025, U.S. Senators Ron Wyden and Jeff Merkley urged Health and Human Services Secretary Robert F. Kennedy Jr. to launch a national vaccination campaign following the first U.S. measles deaths in a decade. They emphasized the need for immediate action to curb the outbreak and protect public health. This call to action reflects a broader commitment to strengthening immunization programs across the region.

U.S. Measles, Mumps, Rubella Vaccines Market Trends

The measles, mumps, and rubella vaccine market in the U.S. is experiencing notable growth, supported by a robust regulatory environment and recent vaccine approvals. In June 2022, GSK plc announced that the U.S. Food and Drug Administration (FDA) approved Priorix-its live MMR vaccine-for active immunization in individuals aged 12 months and older. This approval marked a significant milestone, expanding vaccine options in the U.S. market and enhancing supply resilience. The entry of Priorix not only boosts competition but also supports broader immunization coverage, contributing to public health efforts aimed at controlling and preventing outbreaks of these highly contagious diseases.

Europe Measles, Mumps, Rubella Vaccines Market Trends

Europe measles, mumps, and rubella vaccines market is experiencing steady growth, driven by comprehensive immunization programs and strong healthcare infrastructure. The region benefits from extensive public health policies and EU-wide vaccination efforts that promote MMR immunization. However, challenges such as vaccine hesitancy and economic disparities in certain areas, particularly Eastern Europe, persist. Despite these challenges, Europe continues to make progress in combating these diseases, with vaccination rates generally exceeding 90% in most countries.

The UK measles, mumps, rubella vaccines market is experiencing steady growth, driven by robust public health initiatives and a strong healthcare infrastructure. This growth is supported by comprehensive immunization programs and high vaccination coverage rates. Leading pharmaceutical companies, such as GlaxoSmithKline plc (GSK), play a significant role in the market, offering vaccines like Priorix and collaborating with stakeholders to improve vaccine accessibility and coverage. However, challenges such as vaccine hesitancy persist, necessitating ongoing public health efforts to maintain and enhance immunization rates.

Germany measles, mumps, and rubella vaccines market is witnessing strong growth, supported by stringent public health policies. A key driver is the 2020 law requiring parents to provide proof of measles vaccination before their children can attend schools or daycare centers. This mandate aims to increase immunization rates and curb outbreaks. The regulation has significantly boosted vaccine demand, reinforcing Germany’s commitment to public health and making MMR vaccination a crucial part of the country’s disease prevention strategy.

Asia Pacific Measles, Mumps, Rubella Vaccines Market Trends

Asia Pacific measles, mumps, and rubella vaccines market is anticipated to witness the fastest growth of 9.61% CAGR over the forecast period, driven by regional collaborations and the introduction of innovative vaccines. In November 2023, Indian Immunological Limited (IIL) launched 'Mabella', a live-attenuated measles and rubella vaccine developed in partnership with Vietnam's Polyvac Institute. Unveiled during the 25th anniversary of IIL's Human Biologicals Institute, Mabella has demonstrated proven safety and efficacy through rigorous clinical trials. This launch underscores the region's commitment to enhancing immunization coverage and combating vaccine-preventable diseases among children.

China measles, mumps, and rubella vaccine market is experiencing steady growth, driven by robust national immunization programs and increasing public health awareness. In 2020, approximately 43 million doses of MMR vaccines were approved and released in China, reflecting the country's commitment to widespread immunization efforts. The nation's strong domestic vaccine production capabilities, supported by government initiatives, ensure a stable supply and accessibility of MMR vaccines. Additionally, China's expanding healthcare infrastructure and emphasis on disease prevention contribute to the rising demand for MMR vaccines. These factors collectively position China as a significant player in the global MMR vaccine market, with continued growth anticipated in the coming years.

Latin America Measles, Mumps, Rubella Vaccines Market Trends

Latin America measles, mumps, and rubella vaccine market is experiencing significant growth, propelled by regional immunization initiatives and public health campaigns. A key driver is the Pan American Health Organization's (PAHO) annual Vaccination Week in the Americas (VWA). In April 2024, PAHO, in collaboration with 34 countries, administered over 65 million vaccine doses, including MMR vaccines, during this campaign. This concerted effort underscores the region's commitment to eradicating measles and enhancing immunization coverage.

Middle East and Africa Measles, Mumps, Rubella Vaccines Market Trends

The Middle East and Africa (MEA) measles, mumps, rubella vaccines market is expanding, reflecting increased investment in immunization infrastructure. Governments in South Africa, Egypt, Saudi Arabia, and Gulf states have strengthened routine childhood vaccination schedules, while WHO and UNICEF-backed campaigns target remote and underserved communities. In addition, rapid outbreak responses and mass vaccination drives-especially among urban centers and refugee populations-are sustaining demand and improving MMR coverage across the region.

Key Measles, Mumps, Rubella Vaccine Company Insights

Some of the key players operating in the market are Merck & Co., Inc.; GS; Serum Institute of India Pvt. Ltd.; Sanofi; Shanghai Institute of Biological Products; Beijing Institute of Biological Products; Biological E Ltd.; Sinovac; among others. New product launches, mergers and acquisitions, and collaborations are some of the major strategies adopted by these players to counter the stiff competition.

Recent Developments

• In April 2025, as Texas faced its second measles-related death amid a continuing outbreak, HHS Secretary Robert F. Kennedy Jr. took to social media to endorse the MMR vaccine, appearing to retract some of his earlier statements on vaccines and the outbreak.

• In March 2023, Merck announced that the FDA had approved adding an intramuscular (IM) option to the U.S. Product Insert for its MMRV. Until now, these long‑standing vaccines in the U.S. have only been delivered via subcutaneous (SC) injection.

• In November 2024, Saudi Arabia’s Ministry of Health rolled out a nationwide measles and rubella vaccination campaign. Launched on November 3, it reached every region and governorate across the Kingdom. As part of the Health Sector Transformation Program under Saudi Vision 2030, the initiative aims to eradicate both diseases by 2028, bolstering national and global health security.

Measles, Mumps, Rubella Vaccines Market Report Scope

Global Measles, Mumps, Rubella Vaccines Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global measles, mumps, rubella vaccine market report on the basis of type, targeted population, distribution channel, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Monovalent

  • Trivalent (combined MMR)

  • Tetravalent

• Targeted Population Outlook (Revenue, USD Million, 2018 - 2030)

  • Infants and children (9 months to 12)

  • Adults

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals and Healthcare Institutions

  • Vaccine Centers and Public Health Clinics

  • Pediatric and Private Healthcare Clinics

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Denmark

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait